Serial 79440320

What this means for you

Approved and waiting on proof of use. It will register unless the applicant drops it, and its 21 Oct 2025 filing date already counts against anyone who files later.

Record

Serial number

79440320

Mark type

Design / logo

Filed

21 Oct 2025

Attorney of record

R. Peter Spies

Goods and services

• Class 001 — Chemicals: Biochemicals, namely, monoclonal antibodies for in vitro scientific or research use; biomolecule labelling kits comprising reagents for use in scientific research; biochemicals namely, polypeptides for in vitro research use; diagnostic preparations for scientific or research use; reagents for scientific or medical research use; diagnostic preparations for research laboratory use; diagnostic reagents for scientific or research use; cell growth media for growing cells for use in scientific research; cell culture reagents for scientific and research use; stem cells for research or scientific purposes
• Class 009 — Scientific and electric apparatus: Scientific apparatus and instruments, namely, microfluidic in vitro flow cells for modeling neurobiological processes; apparatus for high-content imaging, optical and electrophysiological readouts for neuroscience drug discovery in the nature of electronic apparatus for electrophysiological and optical measurement and testing of cells for neuroscience drug discovery; computer software, recorded, for functional and morphological cell-based analytics and for analyzing data from high-content imaging, optical and electrophysiological readouts in the field of neuroscience drug discovery
• Class 041 — Education and entertainment services: Publishing of texts in the nature of book publishing, reporting of texts in the nature of current event reporting, and writing of texts in the nature of writing of articles for professional journals other than for advertising or publicity; teaching in the field of neuroscience, pharmaceutical research, and drug discovery; arranging and conducting conferences and seminars in the field of neuroscience, pharmaceutical research, and drug discovery
• Class 042 — Scientific and technological services: Scientific research and development; drug discovery services; development of pharmaceutical preparations and medicines; pharmaceutical drug development services; research on the subject of pharmaceuticals; conducting early evaluations in the field of new pharmaceuticals; consultancy in the field of pharmaceutical research; inspection of pharmaceuticals; laboratory research services relating to pharmaceuticals; pharmaceutical product evaluation; pharmaceutical research and development; biological research; biological analysis; biological product development services; biological research laboratory services, namely, phenotypic and target-based assay development, assay validation, compound screening and lead optimization using advanced in vitro neuroscience platforms; biological research, clinical research in the field of neuroscience for modeling neurological and neurodegenerative diseases and medical research; medical and pharmacological research services; scientific research for medical purposes; research and development in the field of microorganisms and cells; chemical engineering; chemistry services, namely, compound screening and lead optimization for neuroscience drug discovery; clinical research in the field of neuroscience and neurodegenerative diseases; medical research laboratories; technological research in the field of biotechnology, functional genomics, and gene modulation; industrial analysis in the nature of safety and efficacy assessments for pharmaceutical research and industrial research services in the field of pharmaceutical and biotechnology research and development; blood analysis services for scientific research services; blood analysis services for scientific research purposes; biochemical research and development; pharmaceutical research and development for the pharmaceutical industry; research and development in the field of biotechnology; research and development in the pharmaceutical and biotechnology fields; provision of information and data relating to medical and veterinary research and development, namely, providing information and data relating to target discovery, target validation, and lead discovery in the field of neuroscience drug discovery; research and development services in the field of medical preparations; cell culture services for scientific and research purposes, for others

Owner

• Cellectricon AB, SE

Prosecution history

• 16 Oct 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
• 16 Oct 2026 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
• 16 Oct 2026 — EXAMINER'S AMENDMENT ENTERED
• 16 Oct 2026 — EXAMINERS AMENDMENT E-MAILED
• 16 Oct 2026 — EXAMINERS AMENDMENT -WRITTEN
• 01 Jul 2026 — NOTIFICATION OF FINAL REFUSAL EMAILED
• 01 Jul 2026 — FINAL REFUSAL E-MAILED
• 01 Jul 2026 — FINAL REFUSAL WRITTEN
• 20 May 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 20 May 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
• 20 May 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
• 30 Apr 2026 — REFUSAL PROCESSED BY IB
• 10 Apr 2026 — NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
• 10 Apr 2026 — REFUSAL PROCESSED BY MPU
• 08 Mar 2026 — NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW